An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania
Part of paid clinical trials in Garden Grove, California.
- Sponsor
- Neurocrine Biosciences
- Study ID
- NCT07288320
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- Bipolar I Disorder
- Mania
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 65 Years
- Healthy Volunteers
- Not accepted
Interventions
- NBI-1117568 — DRUGOral administration
- Placebo — DRUGOral administration
Study Details
The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving manic symptoms in adults with bipolar I disorder who are currently experiencing an episode of mania with or without mixed features.
Key Dates
- Start date
- Dec 24, 2025
- Status verified
- Mar 2026
- Primary completion
- Feb 29, 2028
- Completion
- Feb 29, 2028
Study Design
- Enrollment
- 150 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: NBI-1117568Participants will receive NBI-1117568.
- Placebo Comparator: PlaceboParticipants will receive placebo matching NBI-1117568.
Primary Outcome Measure
Change From Baseline in Young Mania Rating Scale (YMRS) Total Score at Day 21 [ Time Frame: Baseline, Day 21 ]
Central Contacts
- Neurocrine Medical Information Call Center1-877-641-3461
Locations (6)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Neurocrine Clinical Site | Garden Grove | California | 92845 | - |
| Neurocrine Clinical Site | Hollywood | California | 33024 | - |
| Neurocrine Clinical Site | San Diego | California | 92123 | - |
| Neurocrine Clinical Site | Atlanta | Georgia | 30331 | - |
| Neurocrine Clinical Site | Gaithersburg | Maryland | 20877 | - |
| Neurocrine Clinical Site | Marlton | New Jersey | 08053 | - |
Find similar trials in Garden Grove, CA
By condition
By specialty
Related Studies
- A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.PHASE3 · Recruiting · AbbVie · Bentonville, Arkansas
- Long-term Safety Extension Study of OLZ/SAM in Pediatric SubjectsPHASE3 · Enrolling By Invitation · Alkermes, Inc. · Dothan, Alabama
- Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I DisorderPHASE3 · Recruiting · Alkermes, Inc. · Dothan, Alabama
- Children's Bipolar Network Treatment Trial IRecruiting · University of California, Los Angeles · Los Angeles, California